| abstract |
The present invention relates generally to the field of nicotinic acetylcholine receptor (nACh receptor) ligands, activation of nACh receptors, and treatment of defective or dysfunctional nicotinic acetylcholine receptors, particularly brain disease states. The invention further relates to novel compounds (indazoles and benzothiazoles) that act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. |